Daxibotulinumtoxina PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
93384-43-1
Molecular formula
C6708H10359N1729O1995S32
Molecular weight
148171.53 g/mol
Drug class
Botulinum neurotoxin type Along-acting neuromuscular blocking biologic
Mechanism of action
Enters cholinergic nerve terminals and cleaves SNAP-25, a presynaptic SNARE protein required for acetylcholine-vesicle fusion, thereby inhibiting acetylcholine release and producing temporary chemodenervation of the injected muscle.
Indications / reported uses
Temporary improvement in moderate-to-severe glabellar lines in adults
Treatment of cervical dystonia in adults; product-specific potency units are not interchangeable with other botulinum toxin products
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Daxibotulinumtoxina PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Daxibotulinumtoxina Permitted Daily Exposure (PDE) report (the Daxibotulinumtoxina PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Daxibotulinumtoxina Occupational Exposure Limit (OEL) report (the Daxibotulinumtoxina OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.